Nektar Therapeutics CEO Robin sells 429 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nektar Therapeutics President & CEO Howard W. Robin reported a 429-share sale to cover required tax withholding tied to vesting of his RSUs on November 17, 2026; the footnote says it was not discretionary. The weighted-average sale price was $35.85 per share. Robin directly held 54,198 shares afterward; a separate entry lists 28 shares held indirectly by his spouse. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 429 | $35.85 | $15K |
| Holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
- F2. This transaction was executed in multiple trades at prices ranging from $35.57 to $36.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Key Figures
Key Terms
RSUs financial
weighted average sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What price range did Howard W. Robin's NKTR sale execute at?
AI-generated analysis. How Rhea-AI works. Not financial advice.